Retraction: Concomitant Targeting of EGF Receptor, TGF-beta and Src Points to a Novel Therapeutic Approach in Pancreatic Cancer (PLoS ONE (2012) 7: 6 (e39684) DOI: 10.1371/journal.pone.0039684);Concomitant targeting of EGF receptor, TGF-beta and Src points to a novel therapeutic approach in pancreatic cancer

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Deharvengt, Sophie ^a   Marmarelis, Melina ^a,c   Korc, Murray ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; SSKI 606; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL LEVEL; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE SILENCING; GENE VECTOR; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

MUS MUSCULUS;

EID: 84862983498     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0233436     Document Type: Erratum

References (53)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics CA: Cancer J Clin 62: 10-29.
2. Xiong HQ, Carr K, Abbruzzese JL, (2006) Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions. Drugs 66: 1059-72.
3. Lim JE, Chien MW, Earle CC, (2003) Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surgery 237: 74-85.
4. Kern SE, (2000) Molecular genetic alterations in ductal pancreatic adenocarcinomas. Med Clin North Am 84: 691-5.
5. Korc M, (2007) Pancreatic cancer-associated stroma production. Am J Surgery 194: S84-6.
6. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, et al. (1997) Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57: 3126-30.
7. Korc M, (1998) Role of growth factors in pancreatic cancer. Surg Oncol Clin North America 7: 25-41.
8. Citri A, Yarden Y, (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-16.
9. Kang JS, Liu C, Derynck R, (2009) New regulatory mechanisms of TGF-beta receptor function. Trends Cell Biol 19: 385-94.
10. Neesse A, Michl P, Frese KK, Feig C, Cook N, et al. (2011) Stromal biology and therapy in pancreatic cancer. Gut 60: 861-8.
11. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-6.
12. Preis M, Korc M, (2010) Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biol Therap 9: 754-63.
13. Rowland-Goldsmith MA, Maruyama H, Kusama T, Ralli S, Korc M, (2001) Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin Cancer Res 7: 2931-40.
14. Rowland-Goldsmith MA, Maruyama H, Matsuda K, Idezawa T, Ralli M, et al. (2002) Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Therap 1: 161-7.
15. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, et al. (2008) LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 7: 829-40.
16. Sempere LF, Gunn JR, Korc M, (2011) A novel three-dimensional culture system uncovers growth stimulatory actions by TGF-beta in pancreatic cancer cells. Cancer Biol Therap 12: 198-207.
17. Okabe T, Yamaguchi N, Ohsawa N, (1983) Establishment and characterization of a carcinoembryonic antigen (CEA)-producing cell line from a human carcinoma of the exocrine pancreas. Cancer 51: 662-8.
18. Morgan RT, Woods LK, Moore GE, Quinn LA, McGavran L, et al. (1980) Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma. In J Cancer 25: 591-8.
19. Naldini L, Blomer U, Gage FH, Trono D, Verma IM, (1996) Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 93: 11382-8.
20. Fukasawa M, Korc M, (2004) Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res 10: 3327-32.
21. Smith JJ, Derynck R, Korc M, (1987) Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Proc Natl Acad Sci U S A 84: 7567-70.
22. Ebert M, Yokoyama M, Kobrin MS, Friess H, Lopez ME, et al. (1994) Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res 54: 3959-62.
23. Yokoyama M, Funatomi H, Hope C, Damm D, Friess H, et al. (1996) Heparin-binding EGF-like growth factor expression and biological action in human pancreatic cancer cells. Int J Oncol 8: 289-95.
24. Baldwin RL, Korc M, (1993) Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1. Growth factors 8: 23-34.
25. Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ, et al. (1990) The c-erb B-2 proto-oncogene in human pancreatic cancer. Journal Pathol 161: 195-200.
26. Hruban RH, Wilentz RE, Kern SE, (2000) Genetic progression in the pancreatic ducts. American J Pathol 156: 1821-5.
27. Kolb A, Kleeff J, Arnold N, Giese NA, Giese T, et al. (2007) Expression and differential signaling of heregulins in pancreatic cancer cells. Int J Cancer 120: 514-23.
28. Matsuda K, Idezawa T, You XJ, Kothari NH, Fan H, et al. (2002) Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. Cancer Res 62: 5611-7.
29. Kolch W, Pitt A, (2010) Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nature Rev Cancer 10: 618-29.
30. Padua D, Massagué J, (2009) Roles of TGFbeta in metastasis. Cell Res 19: 89-102.
31. Mimeault M, Batra SK, (2010) Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies. Pharmacol Rev 62: 497-524.
32. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, et al. (1999) The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 18: 5363-72.
33. Wilde A, Beattie EC, Lem L, Riethof DA, Liu SH, et al. (1999) EGF receptor signaling stimulates SRC kinase phosphorylation of clathrin, influencing clathrin redistribution and EGF uptake. Cell 96: 677-87.
34. Zhang Q, Thomas SM, Xi S, Smithgall TE, Siegfried JM, et al. (2004) SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 64: 6166-73.
35. Heldin CH, Miyazono K, ten Dijke P, (1997) TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390: 465-71.
36. Galliher AJ, Schiemann WP, (2007) Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res 67: 3752-8.
37. Wang SE, Xiang B, Zent R, Quaranta V, Pozzi A, et al. (2009) Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Res 69: 475-82.
38. Park SS, Eom YW, Kim EH, Lee JH, Min DS, et al. (2004) Involvement of c-Src kinase in the regulation of TGF-beta1-induced apoptosis. Oncogene 23: 6272-81.
39. van Meeteren LA, Goumans MJ, Ten Dijke P, (2011) TGF-beta receptor signaling pathways in angiogenesis; emerging targets for anti-angiogenesis therapy. Curr Pharm Biotechnol 12(12): 2108-20.
40. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Büchler M, et al. (1992) Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 90: 1352-60.
41. Folkman J, Ryeom S, (2005) Is oncogene addiction angiogenesis-dependent? Cold Spring Harbor Symposia Quantit Biol 70: 389-97.
42. Felsher DW, (2008) Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch. Lymphatic Res Biol 6: 149-54.
43. Whipple CA, Young AL, Korc M, (2012) A Kras(G12D)-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis. Oncogene 31: 2535-44.
44. Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, et al. (2012) A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res 18: 577-84.
45. Korc M, Meltzer P, Trent J, (1986) Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci U S A 83: 5141-4.
46. Ebert M, Yokoyama M, Kobrin MS, Friess H, Lopez ME, et al. (1994) Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res 54: 3959-62.
47. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, et al. (1996) DPC4 gene in various tumor types. Cancer Res 56: 2527-30.
48. Wagner M, Kleeff J, Lopez ME, Bockman I, Massagué J, et al. (1998) Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer. Int J Cancer 78: 255-60.
49. Mueller KL, Hunter LA, Ethier SP, Boerner JL, (2008) Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res 68: 3314-22.
50. Nagaraj NS, Washington MK, Merchant NB, (2011) Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Clin Cancer Res 17: 483-93.
51. Ma YC, Shi C, Zhang YN, Wang LG, Liu H, et al. (2012) The Tyrosine Kinase c-Src Directly Mediates Growth Factor-Induced Notch-1 and Furin Interaction and Notch-1 Activation in Pancreatic Cancer Cells. PLoS One. 2012 7(3): e33414.
52. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, et al. (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467: 1109-13.
53. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-7.